



Final Appraisal Recommendation

Advice No: 1118 – July 2018

Dalbavancin (Xydalba®) 500 mg powder for concentrate for solution for infusion

Submission by Cardiome UK Ltd

Recommendation of AWMSG

Dalbavancin (Xydalba®) is recommended as an option for restricted use within NHS Wales.

Dalbavancin (Xydalba®) should be restricted for use in the following circumstances within its licensed indication for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults:

- as a second-line treatment of ABSSSI; or
- when methicillin-resistant *Staphylococcus aureus* (MRSA) infection is suspected; or
- on the advice of local microbiologists or infectious disease specialists; and
- the patient is at first hospitalised due to ABSSSI and needs intravenous antibiotics but is allowed early discharge as they don't need further inpatient treatment.

Dalbavancin (Xydalba®) is not recommended for use within NHS Wales outside of these circumstances.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2001), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Date of first issue	July 2018
Last reviewed	December 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1118:
Dalbavancin (Xydalba®) 500 mg powder for concentrate for solution for infusion. July 2018.